NEW YORK, Jan. 5 /PRNewswire/ -- Paul Capital Healthcare today announced that it has agreed to provide up to $100 million to Phase III Development Company S.A.R.L ("P3D"), a company recently established to assist in the management and funding of clinical trials in the European Union.

NEW YORK, Dec. 21 /PRNewswire/ -- Paul Capital Healthcare today announced that it has led an investment to provide more than $100 million to UCB S.A. in exchange for certain payments relating to the sales of products marketed by third parties.

KING OF PRUSSIA, Pa., Jan. 8 /PRNewswire/ -- Prism Pharmaceuticals announced today that it will receive a $10 million milestone payment from Paul Capital Healthcare (formerly Paul Royalty Funds), the healthcare investment platform of Paul Capital.